The effect of Rifampicin (RFP) on atypical mycobacterial diseases were observed in 2 casescaused by M. kansasii, 2 cases by M. scrofulaceum, and 29 cases by M. intracellulare.
RFP was administered orally in the dose of 450 mg once daily before breakfast for 6 months.
One of 2 cases caused by M. kansasii was female, 54 years of age, far advanced, and the other, male, 64 years of age, far advanced. One of 2 cases by M. scrofulaceum was male, 74 years of age, minimal, and the other, male, 59 years of age, moderately advanced. The background factors of 29 cases by M. intracellulare were as follows: male 23 cases, female 6 cases; older than 60 years of age 16, between 40 and 59 years of age 11, younger than 39 years of age 2; minimal 1, moderately advanced 22, far advanced 6 ; cases without cavity 1, with nonsclerotic walled cavity 1, with sclerotic walled cavity 27.
In 2 cases caused by M. kansasii, bacilli were converted to negative and slight improve ment of chest roentgenogram was observed in both cases after treatment with RFP.
In 2 cases by M. scrofulaceum, the therapeutic effects of RFP were not obtained.
In 29 cases by M. intracellulare, the percentage of positive bacilli in sputum before and after administration of RFP was as follows: 2 months before RFP treatment 77.7%, 1 month before 80.7%, and after starting RFP treatment, at 1 month 64.2%, at 2 months 53.8%, at 3 months 70.3%, at 4 months 77.7%, at 5 months 63.3% and at 6 months 73.0%. The change of chest roentgenogram after 6 months treatment was as follows: improved in 0, unchan ged in 25, and deteriorated in 3 cases. It was concluded that the effect of RFP on the atypical mycobacterial diseases caused by M. intracellulare was slight, and only transient negative conversion of bacilli was obtained in limited number of cases after one or two months adminis tration of RFP.
Side effects of RFP was noticed in 2 cases by M. intracellulare; namely, transient elevation of S-GOT in one case, and nausea in the other.
View full abstract